Профиль компании
- Фондовый код
- BNTX
- ISIN-код
- US09075V1026
- Валюта
- US Dollar (USD)
- Дата IPO
- 2019-10-10

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell...